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(ingredient cost = €3243). Potential savings if the cheapest
generic omeprazole equivalent were dispensed (instead of pro-
prietary omeprazole) would be approximately 6.2% of the total
hospital expenditure on PPIs for the period examined. When
follow-up prescriptions in the community were examined
approximately 60% of patients did not receive further PPI med-
ication. Of those who continued to receive a prescription for a
PPI, approximately 30% remained on the PPI prescribed in hos-
pital. CONCLUSIONS: Considering that generic omeprazole
has the same therapeutic indications as proprietary omeprazole,
there exists a case for more generic PPI utilisation in Irish hos-
pitals. However, the fact that lansoprazole is priced comparably
to generic omeprazole is encouraging. Regarding follow-up PPI
prescribing in the community, it appears that where follow-up
prescriptions are issued, GPs are more likely to reproduce the
hospital prescription, rather than switch to an alternative PPI.
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OBJECTIVE: In 2001 a new law was passed to allow Danish
pharmacies to distribute dose dispensed medicine (DDM).
Studies have shown that DDM can reduce medicine costs. Other
studies have evaluated patient satisfaction and compliance. 
No studies have evaluated the health effects of DDM. The objec-
tive of this study was to describe the development in medicine
costs; contacts to GPs; and hospital costs before and after start-
ing on DDM. METHODS: National register analysis of patients
receiving DDM from 2001 to 2004 (n = 19,004). The data set
included medicine use and costs (Danish Medicine Register), hos-
pital admissions (Danish Patient Register), health care contacts
and costs (Health Insurance Register). The analysis covers data
from six months before and after ﬁrst day of DDM. RESULTS:
3.464 patients are included in the 2003 analysis and 4.491 in the
2004 analysis. On average patients used 5.3 DDM and 1.1 med-
icines that could not be dose-dispensed. Approx. 25% of the
total medicine costs were due to dispensing fees. The proportion
of patients with GP contacts decreased (from 0.75 per month to
0.57). The average cost per patient on a semi-annual basis was
115.0 Euro before and 99.7 Euro after (2003 data). The pro-
portion of patients hospitalised decreased from 0.06 per months
before to 0.04 per months after (2003 data) and from 0.07 to
0.04 per months (2004 data). The average cost per patient on a
semi-annual basis was 1445.0 Euro before and 882.0 Euro after
(2003 data). The mean length of stay decreased (from 9 to 6
days) as well as the total number of hospital-days (from 15.397
to 5.909) (2004 data). CONCLUSION: The introduction of
DDM resulted in an increase in medicine costs and a decrease in
health care costs. Both the proportion of patients hospitalised
and the length of stay in hospital decreased.
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OBJECTIVES: Medicines waste, with both public health and
economic impact, has been identiﬁed as a problem within the
Portuguese National Health Service (PNHS). This provided the
rational to identify the extent of medicines wastage due to inad-
equacy of medicines pack sizes to the proposed treatments length
and to further estimate non-used medicines due to patients’ non-
adherence, regardless of packs inadequacy. METHODS: A phar-
macy-based prospective two phase study was carried out. New
medication users were invited to participate. Prescribed pack
sizes were scrutinized to evaluate the extent in which they
matched treatment lengths. First-phase study enrollees were
further invited to participate in a telephone interview for pill
counting at the end of the prescribed treatment period (second
phase of the study). RESULTS: From September 2005 to March
2006, 1501 patients were included in the study ﬁrst phase (mean
age 50.1, 68.6% females). A total of 2098 medicines were dis-
pensed to these patients. The cost of wastage associated with
medicines pack sizes was on average 1.75 € [95% CI: 1.51
€–2.00 €] with 58.5% being charged to the PNHS. This cost was
higher than 4.00 € for anti-inﬂammatory and antirheumatic
products, drugs for acid related disorders, corticosteroids for 
systemic use, drugs for obstructive airway diseases, and anti-
protozoals. However the wastage cost represented more than
25% of total expenditure only for anti-inﬂammatory and
antirheumatic products (28.8%) and corticosteroids for systemic
use (41.1%). Follow-up data was already collected for 1298
patients, so results from wastage due to patients’ non-adherence,
regardless of packs inadequacy, will also be presented. CON-
CLUSIONS: The wastage associated with the size of medicines
packs prescribed is signiﬁcant in particular for some therapeutic
groups. Total wastage is expected to be higher taking into con-
sideration patients’ non-compliance.
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OBJECTIVES: To investigate changes in the distribution of gov-
ernment health resources towards different socio-economic
groups of Thais after implementation of the policy on universal
coverage (UC). Effectiveness of the UC policy in improving
equity in access to health services and distribution of government
health resources were also assessed. METHODS: Four main
steps of beneﬁt incidence analysis were employed in order to
analyze the distribution of the net government health subsidies.
The analysis of beneﬁt incidence between different approaches:
using household income and asset index to classify individual
socio-economic status; and using aggregated and regional gov-
ernment unit subsidies. Data sources comprise the national
household surveys on health service use of individuals in 2001
(before UC) and 2003 (after UC), unit government subsidies for
public and private providers in 2001 & 2003. RESULTS: The
concentration indices of ambulatory services at health centres,
district hospitals, and provincial hospitals were more pro-poor
after UC (changing from −0.29, −0.26, and −0.04 in 2001 to 
−0.36, −0.32, and −0.08 in 2003, respectively). The concentra-
tion indices of hospitalization increased their negative values
from −0.079 in 2001 to −0.121 in 2003. The distribution of net
government health subsidies was more pro−poor after UC with
a change in the concentration indices from −0.044 to −0.123.
There was not a signiﬁcant difference in the distribution of 
government health subsidies when income and asset index were
used as means testing, or using aggregated unit subsidies, com-
pared to regional variations. CONCLUSIONS: The UC policy
